Literature DB >> 9806339

Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents.

H A Wieland1, W Engel, W Eberlein, K Rudolf, H N Doods.   

Abstract

1. The novel Y1-selective argininamide derivative BIBO 3304 ((R)-N-[[4-(aminocarbonylaminomethyl)-phenyl]methyl]-N2-(diphen ylacetyl)-argininamide trifluoroacetate) has been synthesized and was examined for its subtype selectivity, its in vitro antagonistic properties and its food intake inhibitory properties. 2. BIBO 3304 displayed subnanomolar affinity for both the human and the rat Y1 receptor (IC50 values 0.38+/-0.06 nM and 0.72+/-0.42 nM, respectively). The inactive enantiomer of BIBO 3304 (BIBO 3457) had low affinity for both the human and rat Y1 receptor subtype (IC50> 1000 nM). BIBO 3304 showed low affinity for the human Y2 receptor, human and rat Y4 receptor as well as for the human and rat Y5 receptor (IC50 values > 1000 nM). 3. 30 microg BIBO 3304 administered into the paraventricular nucleus inhibited the feeding response induced by 1 microg NPY as well as the hyperphagia induced by a 24 h fast implying a role for Y1 receptors in NPY mediated feeding. The inactive enantiomer had no effect. 4. BIBO 3304 inhibits neither the galanin nor the noradrenaline induced orexigenic response. but it blocked feeding behaviour elicited by both [Leu31, Pro24]NPY and NPY (3 36) suggesting an interplay between different NPY receptor subtypes in feeding behavior. 5. The present study reveals that BIBO 3304 is a subtype selective nonpeptide antagonist with subnanomolar affinity for the Y1 receptor subtype that significantly inhibits food intake induced by application of NPY or by fasting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806339      PMCID: PMC1565641          DOI: 10.1038/sj.bjp.0702084

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors.

Authors:  Y Dumont; R Quirion
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.

Authors:  Y Dumont; A Cadieux; H Doods; L H Pheng; R Abounader; E Hamel; D Jacques; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 3.  Promising new approaches to the management of obesity.

Authors:  I L Mertens; L F Van Gaal
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

4.  Agonists for neuropeptide Y receptors Y1 and Y5 stimulate different phases of feeding in guinea pigs.

Authors:  Anne Lecklin; Ingrid Lundell; Suvi Salmela; Pekka T Männistö; Annette G Beck-Sickinger; Dan Larhammar
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

5.  Endogenous PYY and GLP-1 mediate l-glutamine responses in intestinal mucosa.

Authors:  S Joshi; I R Tough; H M Cox
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 6.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

7.  Mechanisms by which the orexigen NPY regulates anorexigenic α-MSH and TRH.

Authors:  Nicole E Cyr; Anika M Toorie; Jennifer S Steger; Matthew M Sochat; Samantha Hyner; Mario Perello; Ronald Stuart; Eduardo A Nillni
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-15       Impact factor: 4.310

8.  The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.

Authors:  Duc Quyen Chu; Helen M Cox; Soraia K P Costa; Herbert Herzog; Susan D Brain
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

9.  The regulation of veratridine-stimulated electrogenic ion transport in mouse colon by neuropeptide Y (NPY), Y1 and Y2 receptors.

Authors:  Niall P Hyland; Helen M Cox
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

10.  Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect.

Authors:  Markus Fendt; Hugo Bürki; Stefan Imobersteg; Kurt Lingenhöhl; Kevin H McAllister; David Orain; Doncho P Uzunov; Frederique Chaperon
Journal:  Psychopharmacology (Berl)       Date:  2009-07-17       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.